{"id":"https://openalex.org/W2006045154","doi":"https://doi.org/10.1111/j.1365-2125.2004.01799.x","title":"Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses","display_name":"Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses","publication_year":2004,"publication_date":"2004-10-20","ids":{"openalex":"https://openalex.org/W2006045154","doi":"https://doi.org/10.1111/j.1365-2125.2004.01799.x","mag":"2006045154","pmid":"https://pubmed.ncbi.nlm.nih.gov/15496222","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/1884553"},"language":"en","primary_location":{"id":"doi:10.1111/j.1365-2125.2004.01799.x","doi":"https://doi.org/10.1111/j.1365-2125.2004.01799.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.2004.01799.x","pdf_url":null,"source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/1884553","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108806158","display_name":"Chukwuemeka S. Okereke","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151718","display_name":"Eisai (United States)","ror":"https://ror.org/0469x1750","country_code":"US","type":"company","lineage":["https://openalex.org/I4210151718","https://openalex.org/I55881946"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Chukwuemeka S. Okereke","raw_affiliation_strings":["Clinical Pharmacology, Eisai Medical Research Inc., Ridgefield Park, NJ 07660, USA. chuk_okereke@eisai.com","Clinical Pharmacology,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology, Eisai Medical Research Inc., Ridgefield Park, NJ 07660, USA. chuk_okereke@eisai.com","institution_ids":["https://openalex.org/I4210151718"]},{"raw_affiliation_string":"Clinical Pharmacology,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110125853","display_name":"Louis C. Kirby","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Louis Kirby","raw_affiliation_strings":["Clinical Pharmacology,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100328491","display_name":"Dinesh Kumar","orcid":"https://orcid.org/0000-0003-3602-4023","observed_orcids":["https://orcid.org/0000-0003-3602-4023","https://orcid.org/0000-0002-6598-4675","https://orcid.org/0000-0003-4693-0097"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dinesh Kumar","raw_affiliation_strings":["Biometrics Biostatistics,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biometrics Biostatistics,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103558979","display_name":"Edward I. Cullen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Edward I. Cullen","raw_affiliation_strings":["Clinical Pharmacology,","Currently employed as a consultant, Montvale, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology,","institution_ids":[]},{"raw_affiliation_string":"Currently employed as a consultant, Montvale, NJ, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069331466","display_name":"Raymond D. Pratt","orcid":"https://orcid.org/0000-0002-8143-1106","observed_orcids":["https://orcid.org/0000-0002-8143-1106"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Raymond D. Pratt","raw_affiliation_strings":["Clinical Research, and","Currently employed by Shire Pharmaceutical Development Inc., Wayne, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research, and","institution_ids":[]},{"raw_affiliation_string":"Currently employed by Shire Pharmaceutical Development Inc., Wayne, PA, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032549720","display_name":"William A. Hahne","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151718","display_name":"Eisai (United States)","ror":"https://ror.org/0469x1750","country_code":"US","type":"company","lineage":["https://openalex.org/I4210151718","https://openalex.org/I55881946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William A. Hahne","raw_affiliation_strings":["Currently employed by CuraGen Corporation, Branford, CT, USA","Research and Development, Eisai Medical Research Inc., Ridgefield Park, NJ, USA and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Currently employed by CuraGen Corporation, Branford, CT, USA","institution_ids":[]},{"raw_affiliation_string":"Research and Development, Eisai Medical Research Inc., Ridgefield Park, NJ, USA and","institution_ids":["https://openalex.org/I4210151718"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5108806158"],"corresponding_institution_ids":["https://openalex.org/I4210151718"],"apc_list":{"value":4780,"currency":"USD","value_usd":4780},"apc_paid":null,"fwci":1.6948,"has_fulltext":false,"cited_by_count":24,"citation_normalized_percentile":{"value":0.82691412,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"58","issue":"s1","first_page":"41","last_page":"49"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9193999767303467,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9193999767303467,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.05660000070929527,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.007199999876320362,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/donepezil","display_name":"donepezil","score":0.878000020980835},{"id":"https://openalex.org/keywords/levodopa-carbidopa","display_name":"levodopa/carbidopa","score":0.972000002861023},{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":0.949999988079071},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.9369999766349792},{"id":"https://openalex.org/keywords/acetylcholinesterase-inhibitors","display_name":"acetylcholinesterase inhibitors","score":0.9649999737739563},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8579999804496765},{"id":"https://openalex.org/keywords/carbidopa","display_name":"carbidopa","score":0.7680000066757202},{"id":"https://openalex.org/keywords/levodopa","display_name":"levodopa","score":0.6439999938011169},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6069999933242798},{"id":"https://openalex.org/keywords/motor-function","display_name":"motor function","score":0.675000011920929},{"id":"https://openalex.org/keywords/multiple-oral-doses","display_name":"multiple oral doses","score":0.5210000276565552},{"id":"https://openalex.org/keywords/alzheimer-s-disease-comorbidity","display_name":"Alzheimer's disease comorbidity","score":0.7519999742507935},{"id":"https://openalex.org/keywords/plasma-concentration-time-curve","display_name":"plasma concentration-time curve","score":0.3970000147819519},{"id":"https://openalex.org/keywords/steady-state-concentration","display_name":"steady-state concentration","score":0.5009999871253967}],"concepts":[{"id":"https://openalex.org/C2776754145","wikidata":"https://www.wikidata.org/wiki/Q71133637","display_name":"Carbidopa","level":5,"score":0.903125524520874},{"id":"https://openalex.org/C2780904820","wikidata":"https://www.wikidata.org/wiki/Q415081","display_name":"Donepezil","level":4,"score":0.8607922196388245},{"id":"https://openalex.org/C2780304432","wikidata":"https://www.wikidata.org/wiki/Q300989","display_name":"Levodopa","level":4,"score":0.8531414866447449},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6550707817077637},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.582219660282135},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.581710159778595},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5323968529701233},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.5009078979492188},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.44508880376815796},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.4411832094192505},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.34630680084228516},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.3205406069755554},{"id":"https://openalex.org/C2779734285","wikidata":"https://www.wikidata.org/wiki/Q11085","display_name":"Parkinson's disease","level":3,"score":0.3031889498233795},{"id":"https://openalex.org/C2779483572","wikidata":"https://www.wikidata.org/wiki/Q83030","display_name":"Dementia","level":3,"score":0.12766143679618835},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.1274661123752594},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0576818585395813},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000077265","descriptor_name":"Donepezil","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000978","descriptor_name":"Antiparkinson Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000978","descriptor_name":"Antiparkinson Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000978","descriptor_name":"Antiparkinson Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D002230","descriptor_name":"Carbidopa","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D002230","descriptor_name":"Carbidopa","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D002230","descriptor_name":"Carbidopa","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D002800","descriptor_name":"Cholinesterase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D002800","descriptor_name":"Cholinesterase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D002800","descriptor_name":"Cholinesterase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004338","descriptor_name":"Drug Combinations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007189","descriptor_name":"Indans","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007189","descriptor_name":"Indans","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007189","descriptor_name":"Indans","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D007980","descriptor_name":"Levodopa","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007980","descriptor_name":"Levodopa","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007980","descriptor_name":"Levodopa","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1111/j.1365-2125.2004.01799.x","doi":"https://doi.org/10.1111/j.1365-2125.2004.01799.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2125.2004.01799.x","pdf_url":null,"source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:1884553","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/1884553","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Clin Pharmacol","raw_type":"Text"},{"id":"pmid:15496222","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15496222","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of clinical pharmacology","raw_type":"Clinical Trial"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:1884553","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/1884553","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Clin Pharmacol","raw_type":"Text"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":35,"referenced_works":["https://openalex.org/W163876575","https://openalex.org/W168084913","https://openalex.org/W255240257","https://openalex.org/W398009941","https://openalex.org/W1518881239","https://openalex.org/W1531855108","https://openalex.org/W1586533434","https://openalex.org/W1986755316","https://openalex.org/W1989070599","https://openalex.org/W1991201604","https://openalex.org/W1997886955","https://openalex.org/W2030079540","https://openalex.org/W2032908576","https://openalex.org/W2038624143","https://openalex.org/W2047095305","https://openalex.org/W2049047445","https://openalex.org/W2055727638","https://openalex.org/W2057679568","https://openalex.org/W2058132358","https://openalex.org/W2062002803","https://openalex.org/W2073988509","https://openalex.org/W2081285591","https://openalex.org/W2093984329","https://openalex.org/W2104227586","https://openalex.org/W2110765139","https://openalex.org/W2122802187","https://openalex.org/W2137227984","https://openalex.org/W2145262930","https://openalex.org/W2148912013","https://openalex.org/W2163873764","https://openalex.org/W2263696050","https://openalex.org/W2437936461","https://openalex.org/W2767359737","https://openalex.org/W2775750683","https://openalex.org/W3094060626"],"related_works":["https://openalex.org/W1986916753","https://openalex.org/W7098424762","https://openalex.org/W4307658853","https://openalex.org/W2077633683","https://openalex.org/W2412345121","https://openalex.org/W2067888950","https://openalex.org/W3165239269","https://openalex.org/W2004480672","https://openalex.org/W4412095203","https://openalex.org/W1984964370"],"abstract_inverted_index":{"AIM:":[0],"The":[1,204,364,450],"use":[2],"of":[3,9,56,62,69,88,99,106,146,207,218,260,263,290,301,366,456,468,483,510],"acetylcholinesterase":[4],"inhibitors":[5],"for":[6,77,130,149],"the":[7,34,107,143,179,184,194,226,257,377,395,416,454,469,508],"treatment":[8,82],"comorbid":[10],"Alzheimer's":[11],"disease":[12,15],"in":[13,80,293,411,421,453,461,464,477,486],"Parkinson's":[14,196],"(PD)":[16],"patients":[17,48,94,220,270,308,332,368,423],"stabilized":[18],"on":[19,415],"a":[20,86,96,131,474],"levodopa":[21,302,457],"regimen":[22],"may":[23],"potentially":[24],"disrupt":[25],"cholinergic":[26],"balance.":[27],"This":[28],"randomized,":[29],"double-blind,":[30],"crossover":[31],"study":[32,378],"investigated":[33],"safety":[35],"of,":[36],"and":[37,44,116,141,176,193,243,279,299,322,341,354,429,443,499],"possible":[38],"drug-drug":[39,438],"interaction":[40],"between,":[41],"donepezil":[42,71,127,147,234,264,291,317,385,402,427,441,511],"HCl":[43,72,128,148,235,292,386,403,428,442,512],"levodopa/carbidopa.":[45],"METHODS:":[46],"Twenty-five":[47],"with":[49,267,329,481,495],"PD":[50,219,269,294,307,331,367,422,487],"who":[51,232,369,400],"were":[52,65,137,223,252,303,324,407,445,493],"taking":[53],"physician-optimized":[54],"doses":[55,68,145,262],"levodopa/carbidopa":[57,100,108,222,444,484],"(with":[58],"daytime":[59],"dosing":[60,185],"intervals":[61],"4-8":[63],"h)":[64],"administered":[66],"once-daily":[67],"either":[70],"(5":[73],"mg)":[74],"or":[75,361],"placebo":[76,272,310,334,391],"15":[78,144],"days,":[79],"two":[81,470],"periods,":[83],"separated":[84],"by":[85,256],"washout":[87],"at":[89,163,172,371,447],"least":[90,372],"2":[91],"weeks.":[92],"Some":[93],"took":[95,426,432],"second":[97],"dose":[98],"after":[101,119,142,288,316],"4":[102,114],"h,":[103,358],"therefore":[104],"subanalysis":[105],"data":[109],"was":[110,210,380,394,502],"conducted":[111],"up":[112],"to":[113,225,326,473,504],"h":[115,118],"8":[117],"dosing.":[120],"Twenty-six":[121],"healthy":[122,230,398],"matched":[123],"controls":[124,231],"received":[125,233,271,309,333,384,390,401],"open-label":[126],"only,":[129],"single":[132],"15-day":[133],"period.":[134],"Blood":[135],"samples":[136],"collected":[138],"before,":[139],"during":[140,376],"pharmacokinetic":[150],"(PK)":[151],"assessments.":[152],"Pharmacokinetic":[153],"parameters":[154,420],"included":[155,189],"maximum":[156],"attained":[157,167],"plasma":[158,169],"drug":[159,170,180],"concentration":[160,171],"(C(max)),":[161],"time":[162],"which":[164],"C(max)":[165,298,321,336],"is":[166],"(t(max)),":[168],"steady":[173,448],"state":[174],"(C(ss)),":[175],"area":[177],"under":[178],"concentration-time":[181],"curve":[182],"over":[183],"interval.":[186],"Safety":[187],"assessments":[188,217],"monitoring":[190],"adverse":[191,374,478,490],"events,":[192,491],"Unified":[195],"Disease":[197],"Rating":[198],"Scale":[199],"(UPDRS)":[200],"motor":[201,418,465],"examination.":[202],"RESULTS:":[203],"mean":[205,348],"age":[206],"all":[208],"subjects":[209,399],"72.6":[211],"+/-":[212,241,245,277,281,339,343,352,356],"1.3":[213],"years.":[214],"Donepezil":[215],"PK":[216,227,251],"receiving":[221],"similar":[224],"results":[228],"from":[229,413],"only":[236,320,404],"(mean":[237,273,335],"AUC(0-12":[238],"h)=":[239,275],"281.6":[240],"17.6":[242],"268.6":[244],"19.9":[246],"ng.h":[247,283],"ml(-1),":[248,284,346],"respectively).":[249,285],"Carbidopa":[250],"not":[253,459],"significantly":[254],"altered":[255],"concomitant":[258],"administration":[259,289,482,509],"multiple":[261],"HCl,":[265,318],"compared":[266,328,480],"when":[268,306,330,382,388,424,430],"AUC(0-8":[274],"921.8":[276],"160":[278],"821.8":[280],"113":[282],"Four":[286],"hours":[287,315],"patients,":[295],"AUC(0-4":[296],"h),":[297],"C(ss)":[300],"higher":[304,381],"than":[305,387],"(P":[311],"<":[312],"0.05).":[313,363],"Eight":[314],"however,":[319,492],"t(max)":[323,349],"observed":[325,446,506],"change":[327,412,463],"=":[337,350,362],"2652":[338],"429":[340],"2077":[342],"276":[344],"ng":[345],"respectively;":[347,359],"1.7":[351],"0.4":[353],"2.9":[355],"0.5":[357],"P<":[360],"number":[365],"experienced":[370],"one":[373],"event":[375],"(13/25)":[379],"they":[383,389,425,431],"(5/25),":[392],"but":[393],"same":[396],"as":[397],"(13/26).":[405],"There":[406],"no":[408],"significant":[409,437],"differences":[410],"baseline":[414],"UPDRS":[417],"examination":[419],"placebo.":[433],"CONCLUSIONS:":[434],"No":[435],"clinically":[436],"interactions":[439],"between":[440],"state.":[449],"small":[451,475],"changes":[452],"pharmacokinetics":[455],"did":[458],"result":[460],"any":[462],"symptoms.":[466],"Co-administration":[467],"drugs":[471],"led":[472],"increase":[476],"events":[479],"alone":[485],"patients.":[488],"These":[489],"consistent":[494],"donepezil's":[496],"cholinomimetic":[497],"effect,":[498],"their":[500],"incidence":[501],"comparable":[503],"that":[505],"following":[507],"alone.":[513]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":3},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":2}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}